BLAINTRAVENOUSINJECTABLE
Approved
Oct 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
4/8 — Partial
IMULDOSA (ustekinumab-srlf) by Accord Biopharma is igg1κ monoclonal antibodies that bind with specificity to the p40 protein subunit used by both the il-12 and il-23 cytokines. Approved for plaque psoriasis, crohn's disease, ulcerative colitis and 1 more indications. First approved in 2024.
Drug data last refreshed 18h ago
Mechanism of Action
IgG1κ monoclonal antibodies that bind with specificity to the p40 protein subunit used by both the IL-12 and IL-23 cytokines. IL-12 and IL-23 are naturally occurring cytokines that are involved in inflammatory and immune responses, such as natural killer cell activation and CD4+ T-cell…
Indications (4)
Worked on IMULDOSA at Accord Biopharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.